Altimmune(US:ALT)2026-03-06 12:56Financial Performance - Altimmune reported a 105% increase in revenue for the year ended December 31, 2025, totaling $41,000 compared to $20,000 in 2024[500]. - The net loss for the year ended December 31, 2025, was $88,093,000, a decrease of 7% from the net loss of $95,059,000 in 2024[500]. - Total other income (expense), net decreased by $2.4 million in 2025, primarily due to increased interest expense related to a Term Loan[505]. - The accumulated deficit reached $649.5 million as of December 31, 2025, with no revenues generated from product sales to date[508]. Research and Development - Research and development expenses decreased by 19% to $66,432,000 in 2025 from $82,226,000 in 2024, primarily due to the completion of the IMPACT Phase 2b trial for MASH[500][502]. - Altimmune plans to increase research and development expenses in the future to support ongoing clinical trials for pemvidutide in MASH, AUD, and ALD[495]. - The company is pursuing additional indications for pemvidutide, specifically for AUD and ALD, with trials currently underway[482][487]. - The company announced positive 48-week topline results from the IMPACT Phase 2b trial, showing significant improvements in anti-fibrosis NITs[481]. Clinical Trials - The company completed enrollment in the RECLAIM Phase 2 trial for AUD ahead of schedule, targeting approximately 100 subjects[486]. - The FDA granted Fast Track designation to pemvidutide for the treatment of AUD, aimed at expediting its development[484]. Cash Flow and Financing - As of December 31, 2025, the company had cash, cash equivalents, restricted cash, and short-term investments totaling $273.5 million[507]. - Net cash used in operating activities decreased to $67.5 million in 2025 from $79.8 million in 2024, reflecting a $12.3 million improvement[519]. - Net cash used in investing activities was $132.5 million in 2025, primarily due to a $285.4 million purchase of short-term investments[520]. - Net cash provided by financing activities increased significantly to $206.8 million in 2025, compared to $10.0 million in 2024[521]. - The company entered into a Loan and Security Agreement with Hercules Capital, allowing for up to $125.0 million in term loans, with the first two tranches totaling $35.0 million drawn down[509][510]. - The company filed a shelf registration statement allowing for the sale of up to $400.0 million of various securities, effective for three years[512]. - The company raised approximately $25.4 million in net proceeds from at-the-market offerings since inception through December 31, 2025, with $174.2 million remaining available[514]. - The company plans to continue pursuing additional equity or debt financing to address long-term capital needs, particularly for clinical trials[523]. Stock Compensation and Market Risk - The company has incurred significant research and development costs, which are expensed as incurred, impacting cash flow and capital resources[526]. - The company acknowledges a high degree of subjectivity in using option pricing models for estimating stock-based compensation, which may lead to significant differences in future compensation expenses compared to historical reports[533]. - As a "smaller reporting company," the company is not required to provide detailed market risk disclosures as per Item 7A of Regulation S-K[534].